{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,8,2]],"date-time":"2024-08-02T09:05:03Z","timestamp":1722589503249},"reference-count":58,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2013,10,3]],"date-time":"2013-10-03T00:00:00Z","timestamp":1380758400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["PharmacoEconomics"],"published-print":{"date-parts":[[2013,11]]},"DOI":"10.1007\/s40273-013-0091-0","type":"journal-article","created":{"date-parts":[[2013,10,2]],"date-time":"2013-10-02T22:02:36Z","timestamp":1380751356000},"page":"981-990","source":"Crossref","is-referenced-by-count":7,"title":["Aripiprazole for the Treatment and Prevention of Acute Manic and Mixed Episodes in Bipolar\u00a0I Disorder in Children and Adolescents: A NICE Single Technology Appraisal"],"prefix":"10.1007","volume":"31","author":[{"given":"Lesley","family":"Uttley","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ben","family":"Kearns","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shijie","family":"Ren","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matt","family":"Stevenson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2013,10,3]]},"reference":[{"key":"91_CR1","unstructured":"National Institute for Health and Care Excellence. Guide to the single technology appraisal (STA) process. 2006. 9-7-2013."},{"key":"91_CR2","unstructured":"Uttley L, Kearns B, Stevenson MWR, Ren S. Aripiprazole for the treatment and prevention of acute manic and mixed episodes in bipolar disorder in children and adolescents: Evidence Review Group\u2019s report. 5-3-2013. National Institute for Heath Research: health technology assessment programme. 9-7-2013."},{"issue":"5","key":"91_CR3","doi-asserted-by":"crossref","first-page":"347","DOI":"10.2165\/11535680-000000000-00000","volume":"28","author":"M Sculpher","year":"2010","unstructured":"Sculpher M. Single technology appraisal at the UK National Institute for Health and Clinical Excellence. Pharmacoeconomics. 2010;28(5):347\u20139.","journal-title":"Pharmacoeconomics"},{"issue":"5","key":"91_CR4","doi-asserted-by":"crossref","first-page":"351","DOI":"10.2165\/11532160-000000000-00000","volume":"28","author":"MM Rodgers","year":"2010","unstructured":"Rodgers MM, Griffin S, Paulden M, Slack R, Duffy S, Ingram JR, et al. Alitretinoin for severe chronic hand eczema. Pharmacoeconomics. 2010;28(5):351\u201362.","journal-title":"Pharmacoeconomics"},{"issue":"6","key":"91_CR5","doi-asserted-by":"crossref","first-page":"439","DOI":"10.2165\/11532220-000000000-00000","volume":"28","author":"A Bagust","year":"2010","unstructured":"Bagust A, Greenhalgh J, Boland A, Fleeman N, McLeod C, Dickson R, et al. Cetuximab for recurrent and\/or metastatic squamous cell carcinoma of the head and neck. Pharmacoeconomics. 2010;28(6):439\u201348.","journal-title":"Pharmacoeconomics"},{"issue":"2","key":"91_CR6","doi-asserted-by":"crossref","first-page":"133","DOI":"10.2165\/11535770-000000000-00000","volume":"29","author":"M Stevenson","year":"2011","unstructured":"Stevenson M, Pandor A. Febuxostat for the management of hyperuricaemia in patients with gout. Pharmacoeconomics. 2011;29(2):133\u201340.","journal-title":"Pharmacoeconomics"},{"issue":"11","key":"91_CR7","doi-asserted-by":"crossref","first-page":"951","DOI":"10.2165\/11589310-000000000-00000","volume":"29","author":"MG Scotland","year":"2011","unstructured":"Scotland MG, Waugh N, Royle P, McNamee P, Henderson R, Hollick R. Denosumab for the prevention of osteoporotic fractures in post-menopausal women. Pharmacoeconomics. 2011;29(11):951\u201361.","journal-title":"Pharmacoeconomics"},{"issue":"12","key":"91_CR8","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.2165\/11591600-000000000-00000","volume":"29","author":"MR Dickson","year":"2011","unstructured":"Dickson MR, Bagust A, Boland A, Blundell M, Davis H, Dundar Y, et al. Erlotinib monotherapy for the maintenance treatment of non-small cell lung cancer after previous platinum-containing chemotherapy. Pharmacoeconomics. 2011;29(12):1051\u201362.","journal-title":"Pharmacoeconomics"},{"issue":"1","key":"91_CR9","doi-asserted-by":"crossref","first-page":"35","DOI":"10.2165\/11594280-000000000-00000","volume":"30","author":"C McKenna","year":"2012","unstructured":"McKenna C, Maund E, Sarowar M, Fox D, Stevenson M, Pepper C, et al. Dronedarone for the treatment of atrial fibrillation. Pharmacoeconomics. 2012;30(1):35\u201346.","journal-title":"Pharmacoeconomics"},{"issue":"2","key":"91_CR10","doi-asserted-by":"crossref","first-page":"137","DOI":"10.2165\/11591590-000000000-00000","volume":"30","author":"M Holmes","year":"2012","unstructured":"Holmes M, Carroll C, Papaioannou D. Dabigatran etexilate for the prevention of venous thromboembolism in patients undergoing elective hip or knee surgery. Pharmacoeconomics. 2012;30(2):137\u201346.","journal-title":"Pharmacoeconomics"},{"issue":"4","key":"91_CR11","doi-asserted-by":"crossref","first-page":"257","DOI":"10.2165\/11595920-000000000-00000","volume":"30","author":"H Yang","year":"2012","unstructured":"Yang H, Craig D, Epstein D, Bojke L, Light K, Bruce IN, et al. Golimumab for the treatment of psoriatic arthritis. Pharmacoeconomics. 2012;30(4):257\u201370.","journal-title":"Pharmacoeconomics"},{"issue":"6","key":"91_CR12","doi-asserted-by":"crossref","first-page":"483","DOI":"10.2165\/11591550-000000000-00000","volume":"30","author":"MD Boyers","year":"2012","unstructured":"Boyers MD, Jia X, Jenkinson D, Mowatt G. Eltrombopag for the treatment of chronic immune or idiopathic thrombocytopenic purpura. Pharmacoeconomics. 2012;30(6):483\u201395.","journal-title":"Pharmacoeconomics"},{"issue":"11","key":"91_CR13","doi-asserted-by":"crossref","first-page":"991","DOI":"10.2165\/11597160-000000000-00000","volume":"30","author":"J Burch","year":"2012","unstructured":"Burch J, Griffin S, McKenna C, Walker S, Paton J, Wright K, et al. Omalizumab for the treatment of severe persistent allergic asthma in children aged 611 years: a NICE single technology appraisal. Pharmacoeconomics. 2012;30(11):991\u20131004.","journal-title":"Pharmacoeconomics"},{"issue":"12","key":"91_CR14","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.2165\/11597210-000000000-00000","volume":"30","author":"S Whyte","year":"2012","unstructured":"Whyte S, Pandor A, Stevenson M. Bevacizumab for metastatic colorectal cancer. Pharmacoeconomics. 2012;30(12):1119\u201332.","journal-title":"Pharmacoeconomics"},{"issue":"1","key":"91_CR15","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1007\/s40273-012-0006-5","volume":"31","author":"M Kilonzo","year":"2013","unstructured":"Kilonzo M, Hislop J, Elders A, Fraser C, Bissett D, McClinton S, et al. Pazopanib for the first-line treatment of patients with advanced and\/or metastatic renal cell carcinoma. Pharmacoeconomics. 2013;31(1):15\u201324.","journal-title":"Pharmacoeconomics"},{"issue":"2","key":"91_CR16","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1007\/s40273-012-0018-1","volume":"31","author":"D Craig","year":"2013","unstructured":"Craig D, Rice S, Paton F, Fox D, Woolacott N. Retigabine for the adjunctive treatment of adults with partial-onset seizures in epilepsy with and without secondary generalization. Pharmacoeconomics. 2013;31(2):101\u201310.","journal-title":"Pharmacoeconomics"},{"key":"91_CR17","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1007\/s40273-013-0023-z","volume":"3","author":"E Spackman","year":"2013","unstructured":"Spackman E, Rice S, Norman G, Suh DC, Eastwood A, Palmer S. Trastuzumab for the treatment of HER2-positive metastatic gastric cancer. Pharmacoeconomics 2013;3:185\u201394.","journal-title":"Pharmacoeconomics"},{"key":"91_CR18","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1007\/s40273-013-0044-7","volume":"6","author":"R Rafia","year":"2013","unstructured":"Rafia R, Simpson E, Stevenson M, Papaioannou D. Trabectedin for the treatment of advanced metastatic soft tissue sarcoma: a NICE single technology appraisal. Pharmacoeconomics 2013;6:471\u20138.","journal-title":"Pharmacoeconomics"},{"key":"91_CR19","doi-asserted-by":"crossref","unstructured":"Greenhalgh J, Bagust A, Boland A, Blundell M, Oyee J, Beale S et al. Rituximab for the first-line maintenance treatment of follicular non-Hodgkin\u2019s lymphoma. Pharmacoeconomics 2013;5:403\u201313.","DOI":"10.1007\/s40273-013-0043-8"},{"key":"91_CR20","doi-asserted-by":"crossref","unstructured":"Armstrong N, Joore M, van Asselt T, Misso K, Manning N, Tomini F et al. Golimumab for the treatment of ankylosing spondylitis: a NICE single technology appraisal. Pharmacoeconomics 2013;5:415\u201325.","DOI":"10.1007\/s40273-013-0049-2"},{"key":"91_CR21","first-page":"652","volume":"8","author":"J Tosh","year":"2013","unstructured":"Tosh J, Archer R, Davis S, Stevenson M, Stevens JW. Golimumab for the treatment of rheumatoid arthritis after the failure of previous disease-modifying antirheumatic drugs: a NICE single technology appraisal. Pharmacoeconomics 2013;8:652\u201361.","journal-title":"Pharmacoeconomics"},{"key":"91_CR22","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1007\/s40273-013-0050-9","volume":"6","author":"B Kearns","year":"2013","unstructured":"Kearns B, Jones ML, Stevenson M, Littlewood C. Cabazitaxel for the second-line treatment of metastatic hormone-refractory prostate cancer: a NICE single technology appraisal. Pharmacoeconomics 2013;6:479\u201388.","journal-title":"Pharmacoeconomics"},{"key":"91_CR23","doi-asserted-by":"crossref","unstructured":"Faria R, Spackman E, Burch J, Corbacho B, Todd D, Pepper C et al. Dabigatran for the prevention of stroke and systemic embolism in atrial fibrillation: a NICE single technology appraisal. Pharmacoeconomics 2013;7:551\u201362.","DOI":"10.1007\/s40273-013-0051-8"},{"key":"91_CR24","doi-asserted-by":"crossref","unstructured":"Simpson EL, Fitzgerald P, Evans P, Tappenden P, Kalita N, Reckless JPD et al. Bivalirudin for the treatment of ST-segment elevation myocardial infarction: a NICE single technology appraisal. Pharmacoeconomics 2013;4:269\u201375.","DOI":"10.1007\/s40273-013-0036-7"},{"key":"91_CR25","unstructured":"National Institute for Health and Care Excellence. Bipolar disorder (children)\u2014aripiprazole: evaluation report. 6-6-2013. 9-7-2013."},{"key":"91_CR26","unstructured":"Mind tmhc. Understanding bipolar disorder. 2010. 9-7-2013."},{"key":"91_CR27","unstructured":"National Institute for Health and Clinical Excellence. The management of bipolar disorder in adults, children and young people, in primary and secondary care: draft for consultation. National Collaborating Centre for Mental Health Commissioned by the National Institute for Clinical Excellence. 2005. 12-2-2013."},{"issue":"9","key":"91_CR28","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1097\/01.chi.0000170554.23422.c1","volume":"44","author":"M Pavuluri","year":"2005","unstructured":"Pavuluri M, Birhamer B, Naylor M. Pediatric bipolar disorder: a review of the past 10 years. J Am Acad Child Adolesc Psychiatry. 2005;44(9):846\u201371.","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"key":"91_CR29","unstructured":"National Institute of Mental Health. Bipolar disorder in children and teens: a parent\u2019s guide. 2008. Ref Type: Report."},{"issue":"3","key":"91_CR30","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1097\/01.chi.0000194567.63289.97","volume":"45","author":"M DelBello","year":"2006","unstructured":"DelBello M, Kowatch R, Adler C, Stanford KE, Welge JA, Barzman DH, et al. A double-blind randomized pilot study comparing quetiapine and divalproex for adolescent mania. J Am Acad Child Adolesc Psychiatry. 2006;45(3):305\u201313.","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"key":"91_CR31","doi-asserted-by":"crossref","first-page":"e446","DOI":"10.1542\/peds.2008-0841","volume":"123","author":"A Freeman","year":"2013","unstructured":"Freeman A, Youngstrom E, Michalek E, Siegel R, Meyers O, Findling R. Quality of life in pediatric bipolar disorder. Pediatrics. 2013;123:e446\u201352.","journal-title":"Pediatrics"},{"issue":"1","key":"91_CR32","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1089\/cap.2006.0049","volume":"17","author":"J Rademacher","year":"2007","unstructured":"Rademacher J, DelBello MP, Adler C, Stanford K, Strakowski SM. Health-related quality of life in adolescents with bipolar\u00a0I disorder. J Child Adolesc Psychopharmacol. 2007;17(1):97\u2013103.","journal-title":"J Child Adolesc Psychopharmacol"},{"issue":"2","key":"91_CR33","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1016\/j.chc.2008.12.002","volume":"18","author":"EA Youngstrom","year":"2009","unstructured":"Youngstrom EA, Freeman AJ, McKeown Jenkins M. The assessment of children and adolescents with bipolar disorder. Child Adolesc Psychiatr Clin North Am. 2009;18(2):353\u201390.","journal-title":"Child Adolesc Psychiatr Clin North Am"},{"key":"91_CR34","doi-asserted-by":"crossref","unstructured":"Merikangas KR, Cui L, Kattan G, Carlson GA, Youngstrom EA, Angst J. Mania with and without depression in a community sample of US adolescents. Arch Gen Psychiatry. 2012;69(9):943\u2013951. http:\/\/archpsyc.jamanetwork.com\/data\/Journals\/PSYCH\/24834\/yoa120005_943_951.pdf .","DOI":"10.1001\/archgenpsychiatry.2012.38"},{"issue":"9","key":"91_CR35","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.1001\/archpsyc.64.9.1032","volume":"64","author":"C Moreno","year":"2007","unstructured":"Moreno C, Laje G, Blanco C, Jiang H, Schmidt A, Olfson M. National trends in the outpatient diagnosis and treatment of bipolar disorder in youth. Arch Gen Psychiatry. 2007;64(9):1032\u20139.","journal-title":"Arch Gen Psychiatry"},{"key":"91_CR36","unstructured":"Royal College of Paediatrics and Child Health. The use of unlicensed medicines or licensed medicines for unlicensed applications in paediatric practice: policy statement produced by the Joint RCPCH\/NPPG Standing Committee on Medicines. 2000. 11-2-2013."},{"key":"91_CR37","unstructured":"Committee for Medicinal Products for Human Use (CHMP), European Medicines Agency. European Public Assessment Report: procedure no. EMEA\/H\/C\/000471\/II\/0082: Aripiprazole. 2013. 12-2-2013."},{"issue":"10","key":"91_CR38","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.4088\/JCP.09m05164yel","volume":"70","author":"R Findling","year":"2009","unstructured":"Findling R, Nyilas M, Forbes R, McQuade R, Jin N, Iwamoto T, et al. Acute treatment of pediatric bipolar\u00a0I disorder, manic or mixed episode, with aripiprazole: a randomized, double-blind, placebo-controlled study. J Clin Psychiatry. 2009;70(10):1441\u201351.","journal-title":"J Clin Psychiatry"},{"key":"91_CR39","doi-asserted-by":"crossref","first-page":"756","DOI":"10.4088\/JCP.08m04726","volume":"70","author":"S Tramontina","year":"2009","unstructured":"Tramontina S, Zeni C, Ketzer C, Pheula G, Narvaez J, Rohde L. Aripiprazole in children and adolescents with bipolar disorder comorbid with attention-deficit\/hyperactivity disorder: a pilot randomized clinical trial. J Clin Psychiatry. 2009;70:756\u201364.","journal-title":"J Clin Psychiatry"},{"key":"91_CR40","unstructured":"Jing Zhang DA. FDA clinical review: Abilify: Aripiprazole: NDA 21436\/SE5-021. US Food and Drug Administration. 14-2-2008. 12-2-2013."},{"key":"91_CR41","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1111\/j.1399-5618.2009.00750.x","volume":"11","author":"M Haas","year":"2009","unstructured":"Haas M, DelBello M, Pandina G, Kushner S, Van Hove I, Augustyns I, et al. Risperidone for the treatment of acute mania in children and adolescents with bipolar disorder: a randomized, double-blind, placebo-controlled study. Bipolar Disord. 2009;11:687\u2013700.","journal-title":"Bipolar Disord"},{"key":"91_CR42","unstructured":"AstraZeneca. NDA 20-639\/S-045 (acute schizophrenia) and S-046 (acute bipolar mania). Seroquel\u00ae (quetiapine fumarate) tablets for the treatment of pediatric patients with schizophrenia (13\u201317 years old) or bipolar mania (10\u201317 years old). Briefing document for Psychopharmacologic Drugs Advisory Committee Meeting of June 9 and 10, 2009."},{"issue":"10","key":"91_CR43","first-page":"1547","volume":"164","author":"M Tohen","year":"2007","unstructured":"Tohen M, Kryzhanovskaya L, Carlson G, DelBello M, Wozniak J, Kowatch R, et al. Olanzapine versus placebo in the treatment of adolescents with bipolar mania. Am J Clin Hypn. 2007;164(10):1547\u201356.","journal-title":"Am J Clin Hypn"},{"issue":"6","key":"91_CR44","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1111\/j.1399-5618.2010.00850.x","volume":"12","author":"M Pavuluri","year":"2010","unstructured":"Pavuluri M, Henry D, Findling RL, Parnes S, Carbray J, Mohammed T, et al. Double-blind randomized trial of risperidone versus divalproex in pediatric bipolar disorder. Bipolar Disord. 2010;12(6):593\u2013605.","journal-title":"Bipolar Disord"},{"issue":"5","key":"91_CR45","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1001\/archgenpsychiatry.2011.1508","volume":"69","author":"B Geller","year":"2012","unstructured":"Geller B, Luby J, Joshi P, Wagner K, Emslie G, Walkup J, et al. A randomized controlled trial of risperidone, lithium, or divalproex sodium for initial treatment of bipolar disorder, manic or mixed phase, children and adolescents. Arch Gen Psychiatry. 2012;69(5):515\u201328.","journal-title":"Arch Gen Psychiatry"},{"issue":"Suppl 1","key":"91_CR46","doi-asserted-by":"crossref","first-page":"S33","DOI":"10.1016\/j.jad.2007.02.005","volume":"100","author":"PF Buckley","year":"2007","unstructured":"Buckley PF, Paulsson B, Brecher M. Treatment of agitation and aggression in bipolar mania: efficacy of quetiapine. J Affective Disord. 2007;100(Suppl 1):S33\u201343.","journal-title":"J Affective Disord"},{"issue":"6","key":"91_CR47","doi-asserted-by":"crossref","first-page":"899","DOI":"10.4088\/JCP.v68n0612","volume":"68","author":"T Laursen","year":"2007","unstructured":"Laursen T, Munk-Olsen T, Nordentoft M, Mortensen P. Increased mortality among patients submitted with major psychiatric disorders: a register-based study comparing mortality in unipolar depressive disorder, bipolar affective disorder, schizoaffective disorder, and schizophrenia. J Clin Psychiatry. 2007;68(6):899\u2013907.","journal-title":"J Clin Psychiatry"},{"key":"91_CR48","unstructured":"Office for National Statistics. Historic and projected mortality rates (qx) from the 2010-based UK life tables\u2014principal projection. 2012."},{"key":"91_CR49","unstructured":"Curtis L. Unit costs of health & social care 2011. PSSRU 2011."},{"key":"91_CR50","doi-asserted-by":"crossref","unstructured":"Ara R, Brazier J. Populating an economic model with health state utility values: moving towards better practice. Health Economics and Decision Science Discussion Paper Series 2010; 09\/11.","DOI":"10.1111\/j.1524-4733.2010.00700.x"},{"key":"91_CR51","unstructured":"Otsuka Pharmaceutical Co., Bristol Myers Squibb. Aripiprazole for the treatment and prevention of acute manic episodes in bipolar disorder in children and adolescents [ID305]. 2013."},{"key":"91_CR52","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1007\/s11136-006-0059-z","volume":"15","author":"H Hayhurst","year":"2006","unstructured":"Hayhurst H, Palmer S, Abbott R, Johnson T, Scott J. Measuring health-related quality of life in bipolar disorder: relationship of the EuroQol (EQ-5D) to condition-specific measures. Qual Life Res. 2006;15:1271\u201380.","journal-title":"Qual Life Res"},{"key":"91_CR53","unstructured":"Mangalore R. The utility approach to valuing health states in schizophrenia. Mental Health Res Rev. 2000;7:11\u201315."},{"issue":"7","key":"91_CR54","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1007\/s11136-010-9659-8","volume":"19","author":"S Boyle","year":"2010","unstructured":"Boyle S, Jones G, Walters S. Physical activity, quality of life, weight status and diet in adolescents. Qual Life Res. 2010;19(7):943\u201354.","journal-title":"Qual Life Res"},{"key":"91_CR55","doi-asserted-by":"crossref","unstructured":"Briggs A, Wild D, Lees M, Reaney M, Dursun S, Parry D et al. Impact of schizophrenia and schizophrenia treatment-related adverse events on quality of life: direct utility elicitation. Health Qual Life Outcomes. 2008;6:105.","DOI":"10.1186\/1477-7525-6-105"},{"issue":"7","key":"91_CR56","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1111\/j.1524-4733.2008.00344.x","volume":"11","author":"B Heeg","year":"2008","unstructured":"Heeg B, Buskens E, Botteman M, Caleo S, Ingham M, Damen J, et al. The cost-effectiveness of atypicals in the UK. Value Health. 2008;11(7):1007\u201321.","journal-title":"Value Health"},{"issue":"4","key":"91_CR57","doi-asserted-by":"crossref","first-page":"355","DOI":"10.2165\/00019053-200624040-00006","volume":"24","author":"Z Philips","year":"2006","unstructured":"Philips Z, Bojke L, Sculpher M, Claxton K, Golder S. Good practice guidelines for decision-analytic modelling in health technology assessment. Pharmacoeconomics. 2006;24(4):355\u201371.","journal-title":"Pharmacoeconomics"},{"key":"91_CR58","unstructured":"National Institute for Health and Care Excellence. Bipolar disorder (children)\u2014aripirazole: final appraisal determination. 6-6-2013."}],"container-title":["PharmacoEconomics"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40273-013-0091-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40273-013-0091-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40273-013-0091-0","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,7]],"date-time":"2022-03-07T19:25:51Z","timestamp":1646681151000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40273-013-0091-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,10,3]]},"references-count":58,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2013,11]]}},"alternative-id":["91"],"URL":"https:\/\/doi.org\/10.1007\/s40273-013-0091-0","relation":{},"ISSN":["1170-7690","1179-2027"],"issn-type":[{"value":"1170-7690","type":"print"},{"value":"1179-2027","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,10,3]]}}}